Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02368951
Title Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bayer

Advanced Solid Tumor


Aprutumab ixadotin

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
San Francisco California 94115 United States Details
Santa Monica California 90404-1200 United States Details
New Haven Connecticut 06520 United States Details
Chicago Illinois 60611 United States Details
Baltimore Maryland 21231 United States Details
Saint Louis Missouri 63110 United States Details
New York New York 10016 United States Details
Nashville Tennessee 37232 United States Details
Houston Texas 77030 United States Details
Seattle Washington 98109-1023 United States Details
Seoul 03080 Korea, Republic of Details
Seoul 138-736 Korea, Republic of Details
Singapore 169610 Singapore Details
*Shaded cells indicate that there was no data available from for the field